文献速递临床试验与 GCP基础与转化研究

治疗性血浆置换治疗重症SARS-CoV-2疾病(COVID-19)的初步研究:随机对照试验方案的结构化摘要

A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
PubMed 文献 · Trials · 2020-06-08

该方案为一项多中心、开放标签、随机对照试验,计划纳入约120例需ICU入住的重症/危及生命COVID-19成人患者,评估治疗性血浆置换(TPE)的安全性和28天死亡率。TPE组在常规经验性治疗基础上接受TPE,对照组仅接受常规治疗。主要终点为28天死亡率和TPE安全性,次要终点包括SOFA评分改善、炎症标志物变化、机械通气天数和ICU住院时间。

要点

  • TPE可能通过清除白介素-3、6、8、10、干扰素-γ和肿瘤坏死因子-α减轻细胞因子释放综合征。
  • 每中心每组至少随机20例,计划3-6个月内共随机约120例,1:1分层随机。
  • 主要终点为28天死亡率和TPE安全性,次要终点包括SOFA评分和炎症标志物变化。

核心结论

  • 该方案旨在评估TPE在需ICU入住的重症/危及生命COVID-19成人患者中的安全性和28天死亡率。

研究设计与样本

  • 初步、干预性、开放标签、随机对照多中心试验。
  • 计划每中心每组至少随机20例,共约120例,1:1分层随机,分层因素为ICU中心和PaO2/FIO2比值(>150和≤150)。
  • 随机化使用基于网络的randomize.net服务,可变区组大小为4至8例患者。

关键数值与推荐

  • 纳入标准:年龄≥18岁;插管并入住ICU;重症和/或危及生命COVID-19,SARS-CoV-2感染经RT-PCR确认。
  • 排除标准:既往对血浆置换或其成分(如枸橼酸钠)过敏;至少间隔24小时连续两次SARS-CoV-2 RT-PCR阴性;不需ICU的轻症COVID-19;接受姑息治疗的终末期患者。
  • 干预组接受TPE联合经验性COVID-19治疗,TPE使用Spectra Optia TM血液分离系统配备Depuro D2000吸附柱,首剂1.5个血浆容量,后续隔日或每日1个血浆容量,共5至7次。
  • 血浆替代使用5%白蛋白或新鲜冰冻血浆(凝血病患者:凝血酶原时间>37秒;国际标准化比值>3;活化部分凝血活酶时间>100或纤维蛋白原水平<100 mg/d)。

临床怎么用

  • TPE在重症/危及生命COVID-19患者中作为辅助治疗,需在ICU环境下进行并监测不良反应。
  • 临床应用中需评估凝血功能,根据凝血指标选择白蛋白或新鲜冰冻血浆作为替代液。

局限性

  • 开放标签设计,因TPE设备可见无法设盲,未实施分配隐藏。
  • 初步试验采用便利样本,样本量较小(约120例),可能影响结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety of therapeutic plasma exchange (TPE) in adult patients with serious/life-threatening COVID-19 requiring intensive care unit (ICU) admission, and associated 28-day mortality. Serious and life threatening COVID-19 are defined as per published literature (please, refer to the full protocol, Additional file 1). The rationale is that TPE can remove interleukins-3, 6, 8, 10, interferon-gamma and tumor necrosis factor-alpha. Thus, it may reduce the cytokine release syndrome associated with fulminant COVID-19 disease. TRIAL DESIGN: Pilot, interventional, open-label, randomized controlled multicenter trial. PARTICIPANTS: Inclusion criteria are: 1) age ≥ 18 years old; 2) intubation and intensive care unit (ICU) admission; 3) serious and/or life-threatening COVID-19 (please, refer to the full protocol, Additional file 1). SARS-CoV-2 infection is confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays using QuantiNova Probe RT-PCR kit (Qiagen) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland). Exclusion criteria are: 1) previous allergic reaction to plasma exchange or its ingredients (i.e., sodium citrate), 2) two consecutive negative RT-PCR tests for SARS-CoV-2 at least 24 hours apart, 3) mild COVID-19 not requiring ICU admission and 4) terminally ill patients receiving palliative care. The primary site will be King Saud Medical City (KSMC), Riyadh, Kingdom of Saudi Arabia (KSA). Also, the study will run in ICUs (Ministry of Health Cluster 1; Riyadh) and other centers in KSA pending their institutional review board (IRB) approval. INTERVENTIONS AND COMPARATOR: The intervention group will receive TPE, plus empiric treatment for COVID-19. TPE is administered using the Spectra Optia TM Apheresis System equipped with the Depuro D2000 Adsorption Cartridge (Terumo BCT Inc., USA). The first dose is 1.5 plasma volumes, followed by one plasma volume on alternate days or daily for five to seven total treatments. Spectra Optia TM Apheresis System operates with acid-citrate dextrose anticoagulant (ACDA) as per Kidney Disease Improving Global Outcomes (KDIGO) 2019 guidelines. Plasma is replaced with albumin 5% or fresh frozen plasma in patients with coagulopathy (prothrombin time >37 seconds; international normalized ratio >3; activated partial thromboplastin time >100 or fibrinogen level <100 mg/d). TPE sessions are performed daily over four hours and laboratory markers measured daily. The comparators are controls not receiving TPE but usual empiric treatment for COVID-19 as per institutional, national and international recommendations. Both groups will receive standard ICU supportive care. MAIN OUTCOMES: Primary study end-point is 28-day mortality and safety of TPE in serious and/or life-threatening COVID-19. Safety will be evaluated by the documentation of any pertinent adverse and/or serious adverse effects related to TPE as per institutional, national and international (Food and Drug Administration) guidelines. Secondary outcomes are: i) improvement in Sequential Organ Function Assessment (SOFA) score ; ii) changes in inflammatory markers: serum C-reactive protein, lactate dehydrogenase, ferritin, d-dimers and interleukin-6; iii) days on mechanical ventilation and ICU length of stay. RANDOMIZATION: Eligible consented patients are randomized (1:1 allocation) after stratification by ICU center and two PaO2/FIO2 ratio categories (> 150 and ≤ 150). Randomization occurs in variable block sizes of four to eight patients. A web-based randomization service, randomize.net, is used to allocate patients to their respective strata prior to the intervention or control therapy. BLINDING (MASKING): Given the visibility of TPE machinery, the intervention will be unblinded; hence, no enrollment concealment will be expedited. The lack of allocation concealment will be mitigated by several measures (please, refer to the full protocol, Additional file 1). NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): This pilot randomized trial aims to recruit a convenience sample of patients with serious and/or life-threatening COVID-19. Therefore, at least 20 patients are to be randomized to each group per participating center. We are hoping to consent and randomize approximately 60 patients in each group over a 3 to 6 months period giving a total of 120 participants. TRIAL STATUS: The protocol version 1 was approved 29/04/2020. Recruitment is ongoing, and began on 01/05/2020. We estimate completion by 29/10/2020. TRIAL REGISTRATION: Registered at ISRCTN on 18/05/2020 (ISRCTN21363594; doi.10.1186/ ISRCTN21363594). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Faqihi F, Alharthy A, Alodat M, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol. Trials. 2020. PMID: 32513290. doi:10.1186/s13063-020-04454-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。